AKESO(09926),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

09926 AKESO

Market Closed 03-13 16:08:20

110.200

-0.900

-0.81%

High112.900	Low106.800	Vol6.35M
Open111.100	D1 Closing111.100	Amplitude5.49%
Mkt Cap101.49B	Tradable Cap101.49B	Total Shares921.00M
T/O699.49M	T/O Rate0.69%	Tradable Shares921.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"09926","market":"HK","secType":"STK","nameCN":"AKESO","latestPrice":110.2,"timestamp":1773389300009,"preClose":111.1,"halted":0,"volume":6347115,"delay":0,"changeRate":-0.008100810081008025,"floatShares":921000000,"shares":921000000,"eps":-0.604581,"marketStatus":"Market Closed","change":-0.9,"latestTime":"03-13 16:08:20","open":111.1,"high":112.9,"low":106.8,"amount":699488970,"amplitude":0.054905,"askPrice":110.2,"askSize":543000,"bidPrice":110.1,"bidSize":3000,"shortable":3,"etf":0,"ttmEps":-1.007,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1773624600000},"marketStatusCode":7,"adr":0,"listingDate":1587657600000,"exchange":"SEHK","adjPreClose":111.1,"openAndCloseTimeList":[[1773365400000,1773374400000],[1773378000000,1773388800000]],"volumeRatio":0.691932233775148,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"AKS.HK","impliedVol":0.5666,"impliedVolPercentile":0.6486},"requestUrl":"/m/hq/s/09926","defaultTab":"news","newsList":[{"id":"1142485530","title":"AKESO Shares Surge Nearly 8% in Morning Session as First-in-Class Trispecific Antibody AK150 Enters Clinical Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=1142485530","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1142485530?lang=en_us&edition=fundamental","pubTime":"2026-03-10 09:46","pubTimestamp":1773107201,"startTime":"0","endTime":"0","summary":"AKESO (09926) saw its stock rise nearly 8% during the morning trading session. As of the time of writing, the share price had increased by 7.33% to HK$111.3, with a trading volume of HK$276 million....","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"a3f44e86c3bddb2de2b4a93e8a962fb5","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU0417516738.SGD","BK1161","LU0348735423.USD","LU0348766576.USD","IE00B543WZ88.USD","IE00BPRC5H50.USD","LU0417516902.SGD","BK4588","LU1794554557.SGD","LU2778985437.USD","LU0348827113.USD","09926","LU0348767384.USD","LU1961090484.USD","LU2476274308.USD","VXUS","LU2399975544.HKD","IE00B5MMRT66.SGD","LU0540923850.HKD","LU0348825331.USD","LU0417516571.SGD","LU2476274720.SGD","LU0561508036.HKD","BK1574","LU1720050803.USD","LU0348783233.USD","LU0634319403.HKD","LU0348784397.USD","LU2488822045.USD"],"gpt_icon":0},{"id":"2618642416","title":"Assessing Akeso (SEHK:9926) Valuation After Cervical Cancer Data And New INOVIO Trial Collaboration","url":"https://stock-news.laohu8.com/highlight/detail?id=2618642416","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618642416?lang=en_us&edition=fundamental","pubTime":"2026-03-08 22:15","pubTimestamp":1772979314,"startTime":"0","endTime":"0","summary":"Akeso (SEHK:9926) is back in focus after presenting long term survival data for its bispecific antibody cadonilimab in advanced cervical cancer and announcing a new glioblastoma combo trial collaboration with INOVIO.\nSee our latest analysis for Akeso.\nAkeso shares closed at HK$107.3 after a 5.2% 1 day share price return. While the 30 day share price return of 6.34% contrasts with a 13.75% decline over 90 days, the 47.19% 1 year total shareholder return and 173.03% 3 year total shareholder...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9926/akeso-shares/news/assessing-akeso-sehk9926-valuation-after-cervical-cancer-dat","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9926/akeso-shares/news/assessing-akeso-sehk9926-valuation-after-cervical-cancer-dat","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0417516738.SGD","LU0417516902.SGD","LU2476274720.SGD","LU0348767384.USD","LU0634319403.HKD","LU0348827113.USD","LU1794554557.SGD","LU2488822045.USD","09926","LU0348783233.USD","LU2476274308.USD","LU0348784397.USD","LU0348766576.USD","BK1161","LU0348735423.USD","LU0348825331.USD","IE00B543WZ88.USD","LU0540923850.HKD","LU0417516571.SGD","LU1720050803.USD","LU2778985437.USD","LU0561508036.HKD","IE00BPRC5H50.USD","IE00B5MMRT66.SGD","LU1961090484.USD","BK1574","LU2399975544.HKD"],"gpt_icon":0},{"id":"1131078244","title":"AKESO Shares Surge Over 6% in Morning Session on Novel Brain Cancer Treatment Collaboration","url":"https://stock-news.laohu8.com/highlight/detail?id=1131078244","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1131078244?lang=en_us&edition=fundamental","pubTime":"2026-03-05 10:38","pubTimestamp":1772678314,"startTime":"0","endTime":"0","summary":"AKESO (09926) saw its shares rise more than 6% during the morning trading session. At the time of writing, the stock was up 6.3%, trading at HK$101.3, with a turnover of HK$343 million. The increase...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926","DNA","BK1161","LU0348827113.USD","BK4139","IE00B543WZ88.USD","LU1794554557.SGD","LU0417516738.SGD","LU0540923850.HKD","LU1720050803.USD","LU0634319403.HKD","LU2778985437.USD","LU0348766576.USD","LU2488822045.USD","VT","VXUS","IE00B5MMRT66.SGD","IE00BPRC5H50.USD","LU1961090484.USD","BK4588","BK4585","LU0561508036.HKD","LU0348767384.USD","BK1574","BK4121","LU0348784397.USD","LU0417516571.SGD","LU2476274720.SGD","BK4109","LU2399975544.HKD","LU0348825331.USD","LU0348735423.USD","LU0348783233.USD","LU2476274308.USD","LU0417516902.SGD"],"gpt_icon":0},{"id":"2617993975","title":"Akeso Reports 100% 24-Month Overall Survival in Complete Responders With Cadonilimab in Phase II Cervical Cancer Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2617993975","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617993975?lang=en_us&edition=fundamental","pubTime":"2026-03-05 10:26","pubTimestamp":1772677611,"startTime":"0","endTime":"0","summary":"Akeso Inc. reported updated long-term survival results from the China registrational Phase II COMPASSION-03  study evaluating cadonilimab monotherapy in patients with recurrent or metastatic cervical cancer who had failed prior platinum-containing chemotherapy. The company said the data were presented as a late-breaking oral presentation at ESGO 2026, based on a median follow-up of 26.5 months in 99 efficacy-evaluable patients. In a best overall response-stratified analysis, complete responders had a 24-month overall survival rate of 100% with median overall survival not reached, while partial responders had a 24-month overall survival rate of 63% with median overall survival not reached. Across the overall population, Akeso reported a median overall survival of 17.5 months and 18- and 24-month overall survival rates of 47.8% and 40.9%, respectively.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nNDL1f0Gzd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926","BK1161","LU0348827113.USD","IE00B543WZ88.USD","LU1794554557.SGD","LU0417516738.SGD","LU0540923850.HKD","LU1720050803.USD","LU0634319403.HKD","LU2778985437.USD","LU0348766576.USD","LU2488822045.USD","IE00B5MMRT66.SGD","IE00BPRC5H50.USD","LU1961090484.USD","LU0561508036.HKD","LU0348767384.USD","BK1574","LU0417516571.SGD","LU0348784397.USD","LU2476274720.SGD","LU2399975544.HKD","LU0348825331.USD","LU0348735423.USD","LU0348783233.USD","LU2476274308.USD","LU0417516902.SGD"],"gpt_icon":0},{"id":"2617459607","title":"Cadonilimab Achieves 100% 24-Month Os in Complete Responders in R/M Cervical Cancer Based on Long-Term Phase Ii Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2617459607","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617459607?lang=en_us&edition=fundamental","pubTime":"2026-03-05 10:26","pubTimestamp":1772677595,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nTUA3ZZRZH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE00BPRC5H50.USD","LU2476274720.SGD","LU1961090484.USD","LU0634319403.HKD","LU0417516738.SGD","LU2488822045.USD","LU0348767384.USD","LU2399975544.HKD","LU0417516571.SGD","LU2476274308.USD","BK1574","BK1161","LU1720050803.USD","LU0561508036.HKD","LU2778985437.USD","LU0348766576.USD","LU0348825331.USD","09926","LU1794554557.SGD","LU0348784397.USD","LU0348783233.USD","LU0348827113.USD","LU0348735423.USD","LU0540923850.HKD","LU0417516902.SGD","IE00B543WZ88.USD","IE00B5MMRT66.SGD"],"gpt_icon":0},{"id":"2616355590","title":"Akeso, INOVIO team up to test cadonilimab plus INO-5412 in GBM trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2616355590","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616355590?lang=en_us&edition=fundamental","pubTime":"2026-03-04 21:53","pubTimestamp":1772632390,"startTime":"0","endTime":"0","summary":"Akeso Inc. and INOVIO have entered into a clinical trial collaboration and supply agreement to evaluate Akeso’s cadonilimab, a PD-1/CTLA-4 bispecific antibody, in combination with INOVIO’s DNA immunotherapy candidate INO-5412 for the treatment of glioblastoma. The regimen will be studied in the Phase II INSIGhT adaptive platform trial sponsored by Dana-Farber Cancer Institute, with dosing expected to begin in the second half of 2026.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260304:nNDL8Jjn2K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926","LU0348767384.USD","LU0540923850.HKD","LU1720050803.USD","LU0634319403.HKD","BK1574","LU0348766576.USD","LU0348825331.USD","LU1794554557.SGD","LU0417516571.SGD","LU2778985437.USD","BK4139","LU0417516902.SGD","LU0348783233.USD","IE00B5MMRT66.SGD","LU0348735423.USD","BK4568","LU0348784397.USD","LU0348827113.USD","LU2476274308.USD","IE00B543WZ88.USD","IE00BPRC5H50.USD","LU0417516738.SGD","LU0561508036.HKD","BK4583","INO","BK1161","LU2399975544.HKD","LU2476274720.SGD","LU2488822045.USD","LU1961090484.USD"],"gpt_icon":0},{"id":"2616558296","title":"BRIEF-Inovio And Akeso Announce Clinical Collaboration To Advance Novel Combination Therapy For Glioblastoma (Gbm)","url":"https://stock-news.laohu8.com/highlight/detail?id=2616558296","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616558296?lang=en_us&edition=fundamental","pubTime":"2026-03-04 21:06","pubTimestamp":1772629573,"startTime":"0","endTime":"0","summary":"BRIEF-Inovio And Akeso Announce Clinical Collaboration To Advance Novel Combination Therapy For Glioblastoma (Gbm)March 4 (Reuters) - Akeso Inc 9926.HK:INOVIO AND AKESO ANNOUNCE CLINICAL COLLABORATION","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260304:nTUA4TKXJZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BPRC5H50.USD","LU0417516571.SGD","LU0561508036.HKD","LU0348766576.USD","LU2476274308.USD","IE00B5MMRT66.SGD","09926","BK4139","LU1720050803.USD","LU0348783233.USD","LU1961090484.USD","BK1574","LU0348825331.USD","BK4568","LU2476274720.SGD","LU0348827113.USD","LU2399975544.HKD","LU0634319403.HKD","IE00B543WZ88.USD","INO","LU1794554557.SGD","BK4583","LU0417516738.SGD","LU0417516902.SGD","BK1161","LU2778985437.USD","LU0348784397.USD","LU0348767384.USD","LU0540923850.HKD","LU0348735423.USD","LU2488822045.USD"],"gpt_icon":0},{"id":"2616581105","title":"Inovio and Akeso Announce Clinical Collaboration to Advance Novel Combination Therapy for Glioblastoma (GBM)","url":"https://stock-news.laohu8.com/highlight/detail?id=2616581105","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616581105?lang=en_us&edition=fundamental","pubTime":"2026-03-04 21:05","pubTimestamp":1772629500,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260304:nTUA4TKXJZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","LU0540923850.HKD","IE00B543WZ88.USD","LU0348783233.USD","09926","LU0348767384.USD","LU2399975544.HKD","LU2476274308.USD","LU0417516902.SGD","LU0634319403.HKD","LU0348784397.USD","BK4568","IE00BPRC5H50.USD","LU0417516571.SGD","LU0348766576.USD","IE00B5MMRT66.SGD","BK4139","LU1961090484.USD","LU0561508036.HKD","BK4583","INO","LU1720050803.USD","LU0348735423.USD","LU2778985437.USD","LU0348827113.USD","LU2488822045.USD","LU1794554557.SGD","LU0417516738.SGD","LU0348825331.USD","BK1574","LU2476274720.SGD"],"gpt_icon":0},{"id":"2616558476","title":"Inovio - Dosing in Combination Therapy Trial Expected to Begin in H2 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2616558476","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616558476?lang=en_us&edition=fundamental","pubTime":"2026-03-04 21:05","pubTimestamp":1772629500,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260304:nTUA4TKXJZ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4568","LU0348783233.USD","LU0348825331.USD","LU0540923850.HKD","BK1161","LU0417516738.SGD","LU0348784397.USD","LU2476274720.SGD","BK4139","LU0348735423.USD","LU0417516571.SGD","LU0417516902.SGD","LU1961090484.USD","INO","LU0348767384.USD","IE00BPRC5H50.USD","LU0348766576.USD","LU1720050803.USD","LU0634319403.HKD","BK4583","IE00B5MMRT66.SGD","IE00B543WZ88.USD","LU2399975544.HKD","LU0348827113.USD","LU2778985437.USD","LU0561508036.HKD","09926","LU2476274308.USD","LU2488822045.USD","BK1574","LU1794554557.SGD"],"gpt_icon":0},{"id":"1192298705","title":"AKESO (09926) Announces Monthly Return with No Changes to Share Capital or Issued Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=1192298705","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1192298705?lang=en_us&edition=fundamental","pubTime":"2026-03-04 17:46","pubTimestamp":1772617583,"startTime":"0","endTime":"0","summary":"AKESO (09926) released its Monthly Return for the month ended 28 February 2026. The authorized share capital remained at 5.00 billion ordinary shares, each with a par value of USD 0.00001, totaling...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926"],"gpt_icon":0},{"id":"1159547038","title":"AKESO Shares Climb Nearly 5% in Morning Session Following NDA Acceptance for Mandoqi Monoclonal Antibody","url":"https://stock-news.laohu8.com/highlight/detail?id=1159547038","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1159547038?lang=en_us&edition=fundamental","pubTime":"2026-02-27 13:51","pubTimestamp":1772171489,"startTime":"0","endTime":"0","summary":"AKESO (09926) saw its shares rise nearly 5% during morning trading. At the time of writing, the stock was up 4.22%, trading at HK$106.2, with a turnover of HK$456 million. The increase follows news...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0348827113.USD","LU1961090484.USD","LU2476274308.USD","LU2399975544.HKD","LU0417516571.SGD","09926","LU0417516738.SGD","LU0348825331.USD","LU1720050803.USD","LU2488822045.USD","LU1794554557.SGD","LU0348783233.USD","LU0417516902.SGD","VT","IE00B543WZ88.USD","LU0348767384.USD","BK4588","VXUS","LU2476274720.SGD","LU0561508036.HKD","BK1161","LU0348766576.USD","BK4585","IE00BPRC5H50.USD","LU0540923850.HKD","LU2778985437.USD","LU0348784397.USD","LU0634319403.HKD","IE00B5MMRT66.SGD","LU0348735423.USD","BK1574"],"gpt_icon":0},{"id":"2611120049","title":"Assessing Akeso (SEHK:9926) Valuation After AK139 Trial Approval And Ivonescimab Breakthrough Designation","url":"https://stock-news.laohu8.com/highlight/detail?id=2611120049","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611120049?lang=en_us&edition=fundamental","pubTime":"2026-02-15 23:23","pubTimestamp":1771168997,"startTime":"0","endTime":"0","summary":"Akeso (SEHK:9926) has just received approval in China to start Phase II trials for AK139, a first in class IL-4Ra/ST2 bispecific antibody, targeting seven respiratory and autoimmune conditions.\nSee our latest analysis for Akeso.\nInvestors seem to be weighing Akeso's busy clinical calendar against recent volatility, with a 1 day share price return of 1.54% and 7 day return of 4.36% following the AK139 and ivonescimab updates. The 1 year total shareholder return of 74.92% points to strong...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9926/akeso-shares/news/assessing-akeso-sehk9926-valuation-after-ak139-trial-approva","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9926/akeso-shares/news/assessing-akeso-sehk9926-valuation-after-ak139-trial-approva","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0561508036.HKD","LU1961090484.USD","IE00B5MMRT66.SGD","LU0348735423.USD","LU0348827113.USD","IE00BPRC5H50.USD","BK1574","LU2399975544.HKD","LU0348784397.USD","LU2488822045.USD","LU0348767384.USD","LU0348783233.USD","LU0417516902.SGD","LU0540923850.HKD","09926","LU0348766576.USD","LU0348825331.USD","LU1720050803.USD","LU0634319403.HKD","IE00B543WZ88.USD","BK1161","LU0417516571.SGD","LU2476274720.SGD","LU2476274308.USD","LU0417516738.SGD","LU1794554557.SGD","LU2778985437.USD"],"gpt_icon":0},{"id":"2610598760","title":"Akeso Receives Chinese Approval to Begin Phase II Trials of IL-4Rα/ST2 Bispecific Antibody Across Seven Indications","url":"https://stock-news.laohu8.com/highlight/detail?id=2610598760","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610598760?lang=en_us&edition=fundamental","pubTime":"2026-02-11 17:02","pubTimestamp":1770800555,"startTime":"0","endTime":"0","summary":"Akeso Inc. has received approval from the National Medical Products Administration to initiate Phase II clinical trials for its bispecific antibody AK139 in China. The trials will cover seven indications, including chronic obstructive pulmonary disease , severe bronchial asthma, chronic spontaneous urticaria, allergic rhinitis, chronic rhinosinusitis with nasal polyps, moderate-to-severe atopic dermatitis, and prurigo nodularis. AK139 is the first clinical-stage antibody to target both IL-4Rα and ST2 pathways, and the Phase II studies aim to evaluate its therapeutic potential in respiratory and autoimmune diseases.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akeso Inc. published the original content used to generate this news brief ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nNDL8jL4rt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1961090484.USD","BK1161","LU0348783233.USD","LU0540923850.HKD","LU2488822045.USD","LU0348825331.USD","LU0348827113.USD","LU0417516738.SGD","IE00BPRC5H50.USD","09926","LU0348766576.USD","LU1794554557.SGD","LU1720050803.USD","LU2476274308.USD","LU0348735423.USD","BK1574","IE00B5MMRT66.SGD","LU2399975544.HKD","LU2778985437.USD","LU2476274720.SGD","LU0634319403.HKD","LU0417516571.SGD","LU0561508036.HKD","LU0417516902.SGD","IE00B543WZ88.USD","LU0348767384.USD","LU0348784397.USD"],"gpt_icon":0},{"id":"2609653238","title":"Akeso Reports Promising Phase III Results for Ivonescimab in Advanced Biliary Tract Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2609653238","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609653238?lang=en_us&edition=fundamental","pubTime":"2026-02-06 10:27","pubTimestamp":1770344844,"startTime":"0","endTime":"0","summary":"Akeso Inc. has announced that its bispecific antibody ivonescimab has received its fifth Breakthrough Therapy Designation from the National Medical Products Administration  of China for use in combination with chemotherapy as a first-line treatment for advanced biliary tract cancer . This designation follows previous recognitions for indications in lung cancer and triple-negative breast cancer. A randomized, controlled, multicenter Phase III clinical study  is currently underway, comparing ivonescimab plus chemotherapy to durvalumab plus chemotherapy for first-line treatment of advanced BTC. Patient enrollment for this trial has been completed. Results from a Phase 1b/II study were presented at the 2024 American Society of Clinical Oncology  Annual Meeting, showing an objective response rate of 63.6% and a disease control rate of 100% for ivonescimab plus chemotherapy. The regimen also demonstrated a median progression-free survival of 8.5 months and a median overall survival of 16.8 m","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260206:nNDL3MwHJr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1961090484.USD","BK1161","LU0348783233.USD","LU0540923850.HKD","LU2488822045.USD","LU0348825331.USD","LU0348827113.USD","LU0417516738.SGD","IE00BPRC5H50.USD","09926","LU0348766576.USD","LU1794554557.SGD","LU1720050803.USD","LU2476274308.USD","LU0348735423.USD","BK1574","IE00B5MMRT66.SGD","LU2399975544.HKD","LU2778985437.USD","LU2476274720.SGD","LU0634319403.HKD","LU0417516571.SGD","LU0561508036.HKD","LU0417516902.SGD","IE00B543WZ88.USD","LU0348767384.USD","LU0348784397.USD"],"gpt_icon":0},{"id":"2609323885","title":"Akeso startet Phase-III-Studie mit Ivonescimab zur Erstlinienbehandlung von fortgeschrittenem Gallengangskrebs","url":"https://stock-news.laohu8.com/highlight/detail?id=2609323885","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609323885?lang=en_us&edition=fundamental","pubTime":"2026-02-06 10:27","pubTimestamp":1770344844,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akeso Inc. published the original content used to generate this news brief via PR Newswire  on February 06, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260206:nNDL5KgrXt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2488822045.USD","LU0348783233.USD","IE00BPRC5H50.USD","09926","LU0561508036.HKD","LU0348827113.USD","BK1574","LU0348784397.USD","LU0417516902.SGD","LU1720050803.USD","IE00B543WZ88.USD","LU1961090484.USD","LU2476274720.SGD","IE00B5MMRT66.SGD","LU2476274308.USD","LU2778985437.USD","LU0417516571.SGD","LU0348766576.USD","LU0348825331.USD","LU0348767384.USD","LU2399975544.HKD","LU0348735423.USD","LU0417516738.SGD","BK1161","LU1794554557.SGD","LU0540923850.HKD","LU0634319403.HKD"],"gpt_icon":0},{"id":"1166485515","title":"Akeso, Inc. (09926) Announces Monthly Return for January 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=1166485515","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1166485515?lang=en_us&edition=fundamental","pubTime":"2026-02-05 17:34","pubTimestamp":1770284062,"startTime":"0","endTime":"0","summary":"Akeso, Inc. (09926) reported no changes in its authorized share capital for January 2026, holding at 5,000,000,000 ordinary shares with a total par value of USD 50,000. The number of issued shares...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926"],"gpt_icon":0},{"id":"2608870683","title":"BRIEF-Akeso Granted Exclusive Commercialization Rights For Ebronucimab Injection To Jumpcan Pharmaceutical","url":"https://stock-news.laohu8.com/highlight/detail?id=2608870683","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608870683?lang=en_us&edition=fundamental","pubTime":"2026-02-03 22:55","pubTimestamp":1770130536,"startTime":"0","endTime":"0","summary":"BRIEF-Akeso Granted Exclusive Commercialization Rights For Ebronucimab Injection To Jumpcan PharmaceuticalFeb 3  - Akeso Inc 9926.HK:AKESO GRANTED EXCLUSIVE COMMERCIALIZATION RIGHTS FOR EBRONUCIMAB INJECTION TO JUMPCAN PHARMACEUTICALTO RECEIVE RMB80 MILLION LICENSE FEE AND RMB10 MILLION MILESTONESFurther company coverage: 9926.HK ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nFWN3YZ0D9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0634319403.HKD","LU1961090484.USD","IE00B543WZ88.USD","LU2399975544.HKD","LU2778985437.USD","LU2476274308.USD","LU2476274720.SGD","LU2488822045.USD","LU0348767384.USD","IE00B5MMRT66.SGD","LU0540923850.HKD","LU1720050803.USD","LU0348784397.USD","09926","LU0348766576.USD","IE00BPRC5H50.USD","LU0348825331.USD","BK1574","LU0561508036.HKD","LU0348783233.USD","BK1161","LU0348735423.USD","LU0348827113.USD","LU0417516571.SGD","LU0417516902.SGD","LU0417516738.SGD","LU1794554557.SGD"],"gpt_icon":0},{"id":"2608187904","title":"Akeso Grants Commercialization Rights for Hypercholesterolemia Drug to Hubei Jumpcan Pharmaceutical Unit","url":"https://stock-news.laohu8.com/highlight/detail?id=2608187904","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608187904?lang=en_us&edition=fundamental","pubTime":"2026-02-03 21:17","pubTimestamp":1770124673,"startTime":"0","endTime":"0","summary":"Akeso (HKG:9926) units Akeso Biopharma and AD Pharmaceuticals granted JumpCan Pharmaceutical exclusive commercialization rights for the ebronucimab injection within China, according to a Tuesday Hong ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2778985437.USD","LU2399975544.HKD","LU0417516902.SGD","IE00B543WZ88.USD","LU0348827113.USD","LU2476274308.USD","LU1961090484.USD","BK0077","BK0188","BK1574","BK0012","LU0348784397.USD","LU1794554557.SGD","LU0348767384.USD","LU2488822045.USD","LU0417516738.SGD","LU0348783233.USD","LU0348766576.USD","600566","LU0417516571.SGD","09926","LU0540923850.HKD","LU0634319403.HKD","BK0028","LU0348825331.USD","BK0239","LU1720050803.USD","LU2476274720.SGD","LU0348735423.USD","LU0561508036.HKD","BK0201","BK1161","IE00B5MMRT66.SGD","IE00BPRC5H50.USD","BK0187"],"gpt_icon":0},{"id":"1172082434","title":"Akeso (9926) and JumpCan (600566.SS) Sign Exclusive Commercialization Agreement for 伊喜寧®","url":"https://stock-news.laohu8.com/highlight/detail?id=1172082434","media":"Bulletin Express","labels":["corporation","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1172082434?lang=en_us&edition=fundamental","pubTime":"2026-02-03 19:23","pubTimestamp":1770117810,"startTime":"0","endTime":"0","summary":"Akeso, Inc. (9926) has entered into an agreement with JumpCan Pharmaceutical Group Co., Ltd. and Jiangsu Jiyuan Pharmaceutical Co., Ltd., both wholly owned subsidiaries of Hubei JumpCan...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926"],"gpt_icon":0},{"id":"1165430493","title":"AKESO (09926) Grants Exclusive Commercialization Rights for Yixining® to Jumpcan Pharmaceutical","url":"https://stock-news.laohu8.com/highlight/detail?id=1165430493","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1165430493?lang=en_us&edition=fundamental","pubTime":"2026-02-03 19:16","pubTimestamp":1770117392,"startTime":"0","endTime":"0","summary":"AKESO (09926) announced that its indirect wholly-owned subsidiaries, Zhongshan Akeso Biopharma Co., Ltd. and Kangrong Oriental (Guangdong) Pharmaceutical Co., Ltd. (collectively referred to as...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0348827113.USD","LU0348784397.USD","LU0561508036.HKD","LU2778985437.USD","BK0201","LU1794554557.SGD","LU0540923850.HKD","BK0028","BK0239","BK1574","LU2399975544.HKD","BK0012","LU0348783233.USD","LU0417516738.SGD","LU1961090484.USD","LU0348766576.USD","LU2476274308.USD","600566","LU0348767384.USD","BK1161","LU1720050803.USD","LU2476274720.SGD","LU2488822045.USD","LU0348735423.USD","IE00BPRC5H50.USD","LU0417516902.SGD","LU0417516571.SGD","IE00B5MMRT66.SGD","BK0077","BK0187","LU0634319403.HKD","LU0348825331.USD","BK0188","09926","IE00B543WZ88.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.akesobio.com","stockEarnings":[{"period":"1week","weight":0.027},{"period":"1month","weight":0.0475},{"period":"3month","weight":-0.1149},{"period":"6month","weight":-0.1867},{"period":"1year","weight":0.5565},{"period":"ytd","weight":-0.0248}],"compareEarnings":[{"period":"1week","weight":-0.0113},{"period":"1month","weight":-0.066},{"period":"3month","weight":-0.0197},{"period":"6month","weight":-0.035},{"period":"1year","weight":0.0854},{"period":"ytd","weight":-0.0064}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Akeso Inc is an investment holding company dedicated to the research, development, manufacturing and commercialization of antibody drugs that are affordable to patients worldwide. The Company’s programs covering the therapeutic areas of oncology, autoimmune and metabolic diseases. The Company's products mainly include cadonilimab (PD-1/CTLA-4), ivonescimab (PD-1/VEGF), Ligufalimab (AK117, CD47), Pulocimab (AK109, VEGFR-2), ANNIKO (penpulimab, PD-1), and tagitanlimab (PD-L1) used in oncology fields as well as ebronucimab (PCSK9), ebdarokimab (IL-12/IL-23), and Gumokimab (AK111, IL-17) used in metabolic and autoimmune therapeutic fields.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.003338},{"month":2,"riseRate":0.333333,"avgChangeRate":0.019031},{"month":3,"riseRate":0.5,"avgChangeRate":-0.024306},{"month":4,"riseRate":0.8,"avgChangeRate":0.041218},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.003133},{"month":6,"riseRate":0.666667,"avgChangeRate":0.133235},{"month":7,"riseRate":0.5,"avgChangeRate":0.087867},{"month":8,"riseRate":0.5,"avgChangeRate":-0.007754},{"month":9,"riseRate":0.5,"avgChangeRate":0.036209},{"month":10,"riseRate":0.5,"avgChangeRate":0.046029},{"month":11,"riseRate":1,"avgChangeRate":0.102206},{"month":12,"riseRate":0.333333,"avgChangeRate":0.028279}],"exchange":"SEHK","name":"AKESO","nameEN":"AKESO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"AKESO(09926),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest AKESO(09926) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"AKESO,09926,AKESO股票,AKESO股票老虎,AKESO股票老虎国际,AKESO行情,AKESO股票行情,AKESO股价,AKESO股市,AKESO股票价格,AKESO股票交易,AKESO股票购买,AKESO股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"AKESO(09926),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest AKESO(09926) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}